{"nctId":"NCT00603733","briefTitle":"Canadian Active & Maintenance Modified Pentasa Study","startDateStruct":{"date":"2007-10"},"conditions":["Active Ulcerative Colitis","Remission of Ulcerative Colitis"],"count":288,"armGroups":[{"label":"Pentasa速 modified extended release","type":"EXPERIMENTAL","interventionNames":["Drug: 5-ASA (5-Aminosalicylate)"]},{"label":"Pentasa速","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: 5-ASA (5-Aminosalicylate)"]}],"interventions":[{"name":"5-ASA (5-Aminosalicylate)","otherNames":["Pentasa速","mesalamine"]},{"name":"5-ASA (5-Aminosalicylate)","otherNames":["Pentasa速","mesalamine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria for Active phase:\n\n* Newly diagnosed or recurrent, mild to moderate Ulcerative Colitis patients.\n* Extent of colonic involvement confirmed within the past 36 months\n* UCDAI score of at least 3 but not greater than 8 and a score of at least 1 for endoscopy\n* Screening tests to rule out any abnormalities in stool, heart or kidney.\n* Male or non-pregnant females between 18 to 75 years.\n* Women of childbearing potential to use efficacious contraception as judged by the investigator.\n* Written informed consent given.\n\nInclusion Criteria for Maintenance phase:\n\n* Newly recruited subjects with documented mild to moderate UC entering the Run-in Phase: in clinical remission for at least 1 month and for a maximum of 3 years, and receiving 5-ASA 1.4 to 2.5 g/day for maintenance of quiescent disease\n* Subjects from Active Phase: meeting remission criteria after the 8-week active period\n* Extent of colonic involvement confirmed within the past 36 months by colonoscopy\n* In complete remission at entry into the Maintenance Phase, defined as i) a score of 0 or 1 for stool frequency; ii) a score of 0 for rectal bleeding; iii) a score of 0 for endoscopy findings; and iv) a Physician's Global Assessment (PGA) score of 0 or 1\n* Screening tests to rule out any abnormalities in stool, heart or kidney.\n\nExclusion Criteria:\n\n* Use of 5-ASA products at a dose \\>2.5g/day within 7 days prior to entry.\n* Proctitis, short bowel syndrome, prior bowel surgery, severe UC, other forms of Inflammatory Bowel Disease\n* Infectious diseases, parasites, bacterial pathogens\n* Allergy to aspirin or salicylate\n* Liver or kidney abnormalities\n* Alcohol or drug abuse\n* Pregnancy\n* Cancer\n* Bleeding disorders, ulcers, autoimmune diseases\n* Mental disorders\n* Participation in clinical trial in last 30 days\n* Inability to fill in diary cards / comply with protocol requirements","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Active Phase: Proportion of Active Subjects Achieving Overall Improvement","description":"Overall improvement is defined as either a complete remission or a clinical response to therapy as measured by the Ulcerative Colitis Disease Activity Index (UCDAI).\n\nComplete remission is defined as: i) a score of 0 or 1 for stool frequency; ii) a score of 0 for rectal bleeding; iii) a score of 0 for endoscopy findings and iv) a Physician's Global Assessment (PGA) score of 0 or 1.\n\nA clinical response to therapy in the active disease phase is defined as i) improvement in the baseline PGA score; ii) improvement in endoscopy findings and in at least one other clinical assessment (stool frequency, rectal bleeding); iii) no worsening in any other clinical assessment; iv) a decrease of 2 or more points on the UCDAI score.","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":null},{"groupId":"OG001","value":"69.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Maintenance Phase: Proportion of Subjects Experiencing Relapse","description":"Relapse is defined as a UCDAI score of at least 3 and a score of at least 1 for endoscopy","paramType":"NUMBER","dispersionType":"90% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":null},{"groupId":"OG001","value":"11.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Adverse Events","description":"Safety dataset represents all patients in all study phases exposed to study drug at anytime during study. Safety dataset was a combination of the active, run-in and maintenance phases and therefore it is not possible to report the adverse events per phase.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":null},{"groupId":"OG001","value":"45.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":143},"commonTop":["Headache","Nasopharyngitis","Colitis Ulcerative"]}}}